Clinical trials: Immune Checkpoint Inhibitor-associated Myocarditis
Myocarditis, Cardiac Complication
Evaluation of Reporting of Immune Checkpoint Inhibitor Associated Cardio-vascular Adverse Reactions
Immune checkpoint inhibitors (ICIs) might have high grade immune-related adverse events (irAEs) on the cardio-vascular system. This study investigates reports of cardio-vascular toxicity with treatment including anti-PD1…
- Trial name
- RAFALE (NCT03387540)
- Testing
- ICI
- Where
- France
- Volunteers
- 104 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Myocarditis Acute, Cancer
Abatacept in Immune Checkpoint Inhibitor Myocarditis
The primary aim is to test whether abatacept, as compared to placebo, is associated with a reduction in major adverse cardiac events (MACE) among participants hospitalized with myocarditis secondary to an immune checkpoint…
- Trial name
- ATRIUM (NCT05335928)
- Testing
- Abatacept plus
- Where
- 31 sites in United States, Canada
- Volunteers
- 390 people
- Sponsor
- Massachusetts General Hospital
Immune Checkpoint Inhibitor-associated Myocarditis
ATROPOS: Survival Analysis of ICI-associated Myocarditis
ATROPOS is an international, registry-based observational study of cancer patients with immune checkpoint inhibitor-associated myocarditis (ICI-M).
- Trial name
- ATROPOS (NCT07633587)
- Where
- France
- Volunteers
- 1,500 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Myocarditis, Cardiomyopathies
JOint Use of Database to Identify Risk Factors of CARDio-vascular Toxicity Induced by Immune Checkpoint Inhibitors
Immune checkpoint inhibitors (ICIs) might induce high grade immune-related adverse events (irAEs) involving the cardio-vascular system.
- Conditions
- Myocarditis, Cardiomyopathies, Heart Diseases, Cardiovascular Diseases
- Trial name
- JOCARDITE (NCT04294771)
- Testing
- ICI
- Where
- France
- Volunteers
- 500,000 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Immune Checkpoint Inhibitors Related Myocarditis
ICIAM Rehabilitation Program Study: A Randomized Controlled Trial
Immunotherapy has become a cornerstone in oncology; however, managing its associated adverse events poses a significant clinical challenge.
- Trial name
- NCT07280429
- Testing
- rehabilitation protocol
- Volunteers
- 60 people
- Sponsor
- China-Japan Friendship Hospital